Skip to main content
OpenTrials
Completed

NCT Number: NCT00528697

A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

The purpose of this study is to test if the investigational medication ABT-089 is a safe and effective treatment for children with Attention-Deficit/Hyperactivity Disorder or ADHD.

Completed

Looking for future studies?

Notify Me

Key information

Age range

6 year–12 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Site Reference ID/Investigator# 5999, Little Rock, Arkansas, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Have voluntarily signed an informed consent form
  • Meet diagnostic criteria for attention-deficit/hyperactivity disorder (ADHD) based on detailed evaluation and interview with parent(s)
  • First grade or higher in a school setting 3 days/week
  • Subject is generally in good health based on medical history, physical examination, clinical lab tests, and ECG
  • Subject weighs at least 37 pounds (17 kg)
  • Female subjects of childbearing potential must have a negative urine pregnancy test at screening and baseline and agree to comply with applicable contraceptive requirements
  • Subject and parents have been judged by the study doctor to be reliable to keep required appointments for clinic visits and all tests, including blood draws, and examinations

Exclusion criteria

  • Subject is not functioning at an age-appropriate level intellectually
  • Subject has a current or past diagnosis of bipolar disorder, psychosis, autism, Asperger's syndrome, or pervasive developmental disorder
  • Current diagnosis of obsessive-compulsive disorder, eating disorder, anxiety disorder or depressive disorder requiring treatment of any kind
  • Subject has a history of significant allergic reaction to any drug
  • Subject requires ongoing treatment with any psychiatric medication
  • Subject has a serious medical condition, seizure disorder (except febrile seizures as an infant), or history of substance abuse or dependence

Treatment and study plan

ABT-089

Drug

Subjects will take 0.5 and 1 and/or 5 and/or 10 mg ABT-089 tablets (actual dose based on weight) once daily for 8 weeks.

Atomoxetine

Drug

Subjects will take 10, and/or 18 and/or 25 mg atomoxetine tablets once daily for 8 weeks.

Placebo

Drug

Subject will take a tablet once daily for 8 weeks

Primary outcomes

  1. ADHD-RS-IV (HV) - Administered by study doctor

    Time frame: Screening, Day -1, Day 7, Day 14, Day 28, Day 42, Day 56

Secondary outcomes

  1. Health Outcomes Measurements

    Time frame: Baseline to Final Evaluation of 8-week treatment period

  2. Clinical Global Impression-ADHD-Severity Scale

    Time frame: Baseline to Final Evaluation of 8-week treatment period

  3. Parent Rating Scales

    Time frame: Baseline to Final Evaluation of 8-week treatment period

  4. Teacher Rating Scale

    Time frame: Baseline to Final Evaluation of 8-week treatment period

Sponsors and collaborators

Lead sponsor

AbbVie (prior sponsor, Abbott)

Industry

Registry information

Official study title

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Dose-Ranging Study of the Safety and Efficacy of ABT-089 in Children With Attention Deficit-Hyperactivity Disorder (ADHD)

Important dates

Study start
2007
Primary completion
2008
Study completion
2008
First posted
Sep 12, 2007
Registry last updated
Jan 29, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.